XTL Biopharmaceuticals Ltd. (XTLB) DCF Valuation

XTL Biopharmaceuticals Ltd. (XTLB) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

XTL Biopharmaceuticals Ltd. (XTLB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our XTLB DCF Calculator empowers you to evaluate XTL Biopharmaceuticals Ltd. valuation using real-world financial data, offering complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA .0 -.9 -1.0 -.9 -.8 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .8 .0 .0 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -.8 -.9 -1.0 -.9 -.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 6.7 6.0 6.1 3.7 2.0 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9 99.9
EBITAT -.8 -.9 -1.0 -.9 .0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF .0 -.9 -1.0 -.9 .0 .0 .0 .0 .0 .0
WACC, % 9.15 9.15 9.15 9.15 9.15 9.15 9.15 9.15 9.15 9.15
PV UFCF
SUM PV UFCF .0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -1
Equity Value 1
Diluted Shares Outstanding, MM 545
Equity Value Per Share 0.00

What You Will Get

  • Pre-Filled Financial Model: XTL Biopharmaceuticals Ltd.’s (XTLB) actual data allows for accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Automatic updates provide real-time results as you make adjustments.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasting.

Key Features

  • Comprehensive Financial Data: Gain access to precise pre-loaded historical data and future forecasts for XTL Biopharmaceuticals Ltd. (XTLB).
  • Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: User-friendly charts and summaries to effectively visualize your valuation outcomes.
  • Designed for All Skill Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered XTL Biopharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for XTL Biopharmaceuticals' intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose XTL Biopharmaceuticals Ltd. (XTLB)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of seasoned professionals with extensive experience in biopharmaceutical development.
  • Robust Pipeline: A diverse range of products in various stages of development ensures long-term growth potential.
  • Commitment to Quality: Adherence to the highest regulatory standards guarantees the safety and efficacy of our products.
  • Strong Partnerships: Collaborations with leading research institutions enhance our capabilities and reach.

Who Should Use This Product?

  • Healthcare Investors: Develop comprehensive valuation models for assessing XTL Biopharmaceuticals Ltd. (XTLB) investments.
  • Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform corporate strategies in the biotech sector.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in XTL Biopharmaceuticals Ltd. (XTLB).
  • Students and Educators: Utilize real-world data to learn and teach financial modeling in the biotech industry.
  • Biotech Enthusiasts: Gain insights into how companies like XTL Biopharmaceuticals Ltd. (XTLB) are valued in the market.

What the Template Contains

  • Pre-Filled DCF Model: XTL Biopharmaceuticals Ltd.’s (XTLB) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to XTLB.
  • Financial Ratios: Assess XTLB’s profitability, leverage, and operational efficiency.
  • Editable Inputs: Adjust assumptions such as growth rates, margins, and CAPEX to match your scenarios.
  • Financial Statements: Annual and quarterly reports for comprehensive analysis of XTLB.
  • Interactive Dashboard: Effortlessly visualize key valuation metrics and outcomes for XTLB.

No products were found matching.